This article is mentioned in:

Contents

Introduction

Angiogenesis in ovarian cancer

Bevacizumab in ovarian cancer

Novel drugs targeting angiogenesis through alternative pathways

Current and future developments

Introduction

Ovarian cancer is the most common cause of cancer deaths in women affected by gynecologic tumors. Worldwide, ovarian cancer is diagnosed in 225,000 women each year and accounts for over 125,000 deaths (1). Incidence rates vary greatly depending on the geographic distribution and age; most epithelial ovarian cancer (EOC) is diagnosed in developed countries and in women at the sixth and seventh decades of life (2). EOC is characterized by poor prognosis, resulting in 5-year survival rate of only 30%, because diagnosis is often late (approximately 70% of cases are diagnosed at advanced stage) due to vague initial signs and symptoms. In addition, disease recurrence is frequent in over 70–80% of EOC, despite optimal cytoreduction and adequate adjuvant therapy (3,4). Therefore, new therapeutic strategies are needed to improve outcome of ovarian cancer patients and overcome resistance mechanisms. Targeted therapy represents a viable option for management of these patients; especially angiogenesis inhibitors have shown promising therapeutic results in ovarian cancer, in combination with chemotherapy and also as monotherapy.

Angiogenesis in ovarian cancer

Angiogenesis is a multi-step process essential for tumor growth and metastasis, which involves endothelial cell proliferation, migration and capillary formation. It is responsible for tumor growth through the diffusion of nutrients and oxygen from adjacent capillaries (5–7). Hypoxic state induces pro-angiogenic signaling by activating a protein called hypoxia-inducible factor (HIF) -1α which enters the nucleus and forms a complex with another protein, the HIF-1β. HIF-1 complex plays as a transcription factor targeting many genes responsible of upregulation of growth factors, such as vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), platelet-derived growth factor (PDGF) and their receptors and downregulation of anti-angiogenic factors such as thrombospondin-1 and angiostatin. In addition, HIF-1 targets also other genes involved in different steps of the angiogenic process through matrix remodeling factors (e.g. matrix metalloproteases) and factors mediating the migration/invasion of bone-marrow derived cells, including chemokine receptor CXCR4 and its specific ligand, stromal cell-derived factor-1 (CXCR4/SDF-1) axis involved in tumor neoangiogenesis (8).

Among several pro-angiogenic factors, VEGF plays a crucial role in the proliferation, migration and survival of vascular endothelial cells leading to tumor growth and metastasis development (9–12), also through a direct, autocrine effect on tumor cells (13). Some studies have shown a direct role of VEGF-A in cell proliferation and invasiveness also through AKT/mTOR pathway and by altering the expression of matrix metalloproteinase-2 (14,15).

VEGF levels are elevated in malignant ovarian tumors and so it could be used as a biomarker in combination with other proteins, including carbohydrate antigen-125 (Ca125) or human epididymis protein-4 (HE-4) (16,17). The VEGF expression is able to classify 100% of ovarian cancer of various histotypes (18). High levels of VEGF in ovarian cancer patients is associated with advanced tumor stage (19,20), major incidence of metastases (19), poor progression-free survival (PFS) and overall survival (OS) (21). In addition, it has been demonstrated that VEGF overexpression is correlated with the formation of ascites, carcinomatosis and poor prognosis in ovarian cancer. In preclinical models, the use of an anti-VEGF antibody prevented and reserved the presentation of ascites (22,23), and also its combination with paclitaxel reduced surviving levels (24). On the other hand, anti-angiogenic agents inhibit new blood vessel growth and the haematopoietic and endothelial progenitor cell incorporation, normalize the vasculature and induce endothelial cell apoptosis (25).

Semaphorins and neuropilins are molecules involved in angiogenesis and in ovarian carcinogenesis process. Neuropilins bind to the commonest isoform of VEGF-A and may act as co-receptors to enhance VEGF signaling through VEGFR-1. Semaphorins regulate negatively angiogenesis and EOC patients with a high VEGF/semaphorin ratio have a poor survival, because the reduced expression of semaphorins may play an important role in ovarian cancer progression (26).

In EOC, it has been demonstrated that the overexpression of clusterin, a multivalent glycoprotein with ubiquitous tissue distribution, could be correlated with increased tumor angiogenesis, acting probably as an oncogene in the biology of ovarian cancer (27).

In addition, in EOC, as in other tumors, changes in transcriptional regulation can lead to malignant transformation by causing deregulated cell proliferation, suppression of apoptosis, increased angiogenesis. The Jun proteins (c-Jun, JunD and JunB), like Fos proteins, act as transcription factors by forming heterodimers with Jun proteins are important players in angiogenesis and cellular regulation, enhancing cell proliferation, protecting cells from apoptosis. Jun proteins have also tumor-suppressing functions. In fact, the downregulation of JunD can reduce cell proliferation, Ras-induced malignant transformation and to inhibit tumor-related angiogenesis. So Jun and Fos proteins might also be suitable prognostic factors and therapeutic targets (28,29).

Recent evidence supports the role of ovarian cancer stem cells (CSC), that may be characterized by the combined expression of numerous putative cell surface and intracellular markers, including CD44, epithelial cell adhesion molecule, CD133, CD117, CD90 (Thy-1), CD24 and the intracellular marker (ALDH). CD133+ALDH+ human ovarian CSC were highly angiogenic because they derive from tumor metastases capable of attracting endothelial progenitors to promote angiogenesis (30–32). Another study demonstrated that xenograft tumors derived from CD44+ cells had human CD34 expressing blood vessels suggesting that human ovarian CD44+CSC might have the potential to differentiate into vessels or direct other cells for the formation of vessel cells (33). The relation between angiogenesis and stemness can be reciprocal; not only can CSC regulate angiogenesis but recent studies have also reported that hypoxia may be one of the key attributes in the tumor microenvironment which can regulate the phenotype of CSCs through the activation of oncogenes such as myc and ras, resulting in the expression of HIF-1 and HIF-2 inducing the expression of pluripotent genes such as Oct4, Sox3 and kruppel-like factor-4 (34,35). Hypoxia has been shown to induce epithelial to mesenchymal transition (EMT), a process characterized by the transformation of differentiated epithelial cells into migratory mesenchymal cells, in ovarian CSCs by triggering TWIST1 expression (36) or by autocrine secretion of the transforming growth factor (TGF)-β (37). In addition, cyclin D1 might be involved in sustaining the mesenchymal features of ovarian cancer stem cell-like cells in EMT (38).

Currently, apart from VEGF, many studies are ongoing to identify other molecules and pathways involved in angiogenesis, because angiogenetic process has been established as an important step in carcinogenesis influencing tumor growth and the development of metastases.

Among the novel factors contributing to angiogenetic mechanisms in ovarian cancer, CD147, an extracellular matrix metalloproteinase inducer, has been identified to be overexpressed in ovarian cancers and its gene has two hypoxiainducible factors binding sites. The hypoxic microenvironment constitutes a greater inducer of the overexpression of CD147, which is present in microvesicles derived from epithelial ovarian cancer cells that could promote an angiogenic phenotype in endothelial cells (39–41).

Lysyl oxidase-like-2 (42), among the pro-angiogenetic molecules, is a secreted enzyme which catalyzes the cross-linking of collagen, inhibitor of DNA binding/differentiation-1 (Id1) (43), enhancing human ovarian cancer endothelial progenitor cell proliferation via PI3K/Akt and NF-κB/metalloproteinase-2 (MMP-2) signaling pathways.

There is increasing evidence for epigenetic control of angiogenesis by non-coding microRNAs (miRNAs), which activate messenger RNA degradation or block translation. Endothelial cells express several miRNAs, often induced by hypoxia or VEGF, that have been shown to be involved in angiogenesis of many tumors, including ovarian cancer (44). Two miRNAs, miRNA-199a and miRNA-125b, have been demonstrated to be downregulated in ovarian cancer tissues and cell lines, whereas their overexpression could inhibit tumor-induced angiogenesis through the reduction of HIF-1α and VEGF expression in ovarian cancer cells (45).

Recently, it has been suggested that immune system and angiogenesis could display a reciprocal action. VEGF also exerts an immunosuppressive effect in ovarian cancer through VEGFR2, which is expressed by activated lymphocytes; in fact it is correlated with low levels of IL-12, inhibition of dendritic cell maturation, reduced number of natural killer-T cells and upregulation of regulatory T cells. Moreover, it has been established that the interaction of EOC cells and tumor-associated macrophages lead endothelial cells to promote angiogenesis and to infiltrate the peritoneum, that represent the dominant clinical features of this cancer (46–48).

Bevacizumab in ovarian cancer

Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and neutralizes all biologically active forms of VEGF-A, and so inhibits tumor growth and metastatic disease progression (49). The utility of bevacizumab in combination with chemotherapy is demonstrated in the treatment of many epithelial malignancies cancer, including EOC. Initially bevacizumab was explored in animal models, where it inhibited ascites formation and slowed tumor growth (23). In addition, bevacizumab and other VEGF-targeting agents were able to enhance the effects of chemotherapy by normalization of primitive tumor vasculature with reduction of interstitial fluid pressure, increase of tumor oxygenation, major delivery of cytotoxic drugs (50).

Currently, bevacizumab is the most studied anti-angiogenic drug in EOC in different tumor settings. In addition, it is usually associated with cytotoxic drugs in phase III and phase II studies, but in the past has also been used as monotherapy and some phase II studies of combination of bevacizumab with other anti-angiogenic molecules are ongoing.

Bevacizumab in combination with chemotherapy

Two phase III randomized trials have recently evaluated the addition of bevacizumab to the standard paclitaxel/carboplatin and maintenance therapy with bevacizumab at the end of chemotherapy.

GOG-0218 (51) is a three-arm trial comparing carboplatin and paclitaxel versus carboplatin, paclitaxel and bevacizumab plus or minus maintenance bevacizumab. This trial examined 1,873 patients with advanced (stage III–IV) EOC. PFS was the primary end-point and it was significantly longer in the carboplatin, paclitaxel, bevacizumab and maintenance bevacizumab group compared with the two other groups (median PFS 10.3 months for control; 11.2 months for bevacizumab and chemotherapy plus placebo maintenance; 14.1 months for bevacizumab and chemotherapy plus bevacizumab maintenance). The International Collaborative Ovarian Neoplasm (ICON) 7 study (52) is a two-arm trial comparing carboplatin and paclitaxel versus carboplatin, paclitaxel and bevacizumab followed by maintenance bevacizumab. The trial included 1,528 women with stage IIB–IV disease as well as stage I–IIA disease who have grade 3 or clear cell histology. The primary end-point was PFS, that was significantly better in the bevacizumab arm (PFS at 36 months: 20.3 months in control arm vs. 21.8 months in bevacizumab arm). The results of these studies led to the approval of bevacizumab by European Medicines Agency (EMEA) for first-line treatment of FIGO stage IIIB, IIIC and IV EOC.

Bevacizumab has been also evaluated in relapsed EOC. OCEANS trial (53) is a 2-arm, double-blind study of 484 women with platinum-sensitive recurrent EOC after first-line chemotherapy. This study compared bevacizumab plus carboplatin/gemcitabine with carboplatin/gemcitabine alone. The primary end-point was PFS, which was significantly prolonged by the addition of bevacizumab by 4 months. AURELIA trial (54) is a randomized phase III trial evaluating bevacizumab plus chemotherapy (pegylated liposomal doxorubicin, topotecan, or weekly paclitaxel) in 361 platinum-resistant patients with recurrent EOC. This study concluded that the addition of bevacizumab to chemotherapy in platinum resistant OC provides statistically significant improvement in PFS compared to chemotherapy alone (6.7 months versus 3.4 months, respectively).

Several clinical trials have demonstrated the safety and activity of bevacizumab in combination with cytotoxic chemotherapy agents typically used in platinum-resistant EOC: topotecan, pegylated liposomal doxorubicin, weekly paclitaxel, nab-paclitaxel, low-dose metronomic oral cyclophosphamide (55–60). As summarized in Table I, these studies show that the combination is safe and active in platinum-resistant EOC and suggest bevacizumab may enhance the efficacy of the cytotoxic agent with PFS ranging from 2.8 and 13.9 months, overall survival from 2.8 to 33.2 months, objective rates from 24 to 72.2%. A recent phase II trial (61) of pegylated liposomal doxorubicin and carboplatin plus bevacizumab has showed objective rate of over 70% with PFS of 13.9 months in patients with platinum-sensitive recurrent EOC.

Table I. Phase III and II trials of bevacizumab in patients with epithelial ovarian cancer.

Table I.

Phase III and II trials of bevacizumab in patients with epithelial ovarian cancer.

Trial author/(refs.)	Phase trial	Patient population	Arm	PFS (months)	OS (months)	RR (%)
Chemotherapy plus bevacizumab
First line
GOG-0218	III	1,873	CT	10.3	39.3
Burger et al (51)			CT+BEV	11.2	38.7	NR
			CT+BEV>BEV	14.1	39.7
ICON7	III	1,528	CT	22.4	28.8	48
Perren et al (52)			CT+BEV>BEV	24.1	36.6	67
Relapse
OCEANS	III	484	CG	8.4	35.2	57.4
Aghajanian et al (53)		Platinum-sensitive	CG+BEV	12.4	33.3	78.5
AURELIA	III	361	P/T/PLD	3.4	NR	12.6
Pujane-Lauraine et al (54)		Platinum-resistant	P/T/PLDD+BEV	6.7	NR	30.9
NCI-5789	II	70	Cy+Bev	7.2 (TTP)	NR	24
Garcia et al (55)		Platinum-resistant
McGonigle et al (56)	II	40 Platinum-resistant	T+Bev	10.9 (1 prior regimen) 2.8 (2 prior regimens)	22.9 (1 prior regimen) 2.8 (2 prior regimens)	25
Kudoh et al (57)	II	30 Platinum-resistant	PLD+Bev	6	NR	33
O’Malley et al (58)	II	41	P+Bev	13.2	20.6	63
		Platinum-resistant	P	6.2	9.1
Verschraegen et al (59)	II	46	PLD+Bev	7.8	33.2	30.2
		Platinum-resistant
Tillmanns et al (60)	II	48	Nab-P+Bev	8.08	17.15	50
		Platinum-resistant
Del Carmen et al (61)	II	54	PLD+C+Bev	13.9	NR	72.2
		Platinum-sensitive
Single-agent bevacizumab
Relapse
GOG-0170D	II	62	Bev	4.7	17	21
Burger et al (62)		Platinum-sensitive and platinum-resistant Primary peritoneal cancer
Genentech_AVF 2949g	II	44	Bev	4.4	10.7	16
Cannistra et al (63)		Platinum-sensitive and platinum-resistant Primary peritoneal cancer
Bevacizumab plus other target therapies
Nimeiri et al (64)	II	13 Platinum-sensitive and platinum-resistant	Bev+erlotinib	4.1	11	15.1
Chambers et al (65)	II	40 Platinum-sensitive and platinum-resistant	Bev+erlotinib	4	NR	23.1
Morgan et al (66)	II	31 Platinum-sensitive and platinum-resistant	Bev+ temsirolimus	56% (6-mo PFS)	NR	12
Kohn et al (67)	II	30 Bev-naïve patients	Bev+sorafenib	NR	NR	24

[i] PFS, progression-free survival, OS, overall survival; GOG, Gynecologic Oncology Group; ICON, International Co-operative Group for Ovarian Neoplasia; C, carboplatin; P, paclitaxel; Bev, bevacizumab; G, gemcitabine; T, topotecan; PLD, pegylated liposomal doxorubicin; Cy, cyclophosphamide; NR, not reported.

Single-agent bevacizumab

Two phase II studies (62,63) evaluated also efficacy of single-agent bevacizumab in platinum-pretreated patients with recurrent EOC, reporting acceptable results. The first trial (62), termed GOG-0170D, reported an overall response rate of 21% and median PFS and OS of 4.7 and 17 months in 62 persistent or recurrent EOC or primary peritoneal cancers treated with bevacizumab monotherapy every three weeks. The second study (63), evaluating the efficacy and safety of bevacizumab monotherapy in 44 patients with platinum-resistant EOC who had experienced disease progression during or within 3 months of discontinuing topotecan or pegylated liposomal doxorubicin, showed an objective response rate of 15.9%, median PFS of 4.4 months and median OS of 10.7 months.

Bevacizumab plus other target therapies

Some trials have considered the opportunity of combining bevacizumab with other non-anti-angiogenic biologic agents leading so far to disappointing and inconclusive results in platinum sensitive and platinum-resistant patients. The studies (64,65) evaluating bevacizumab plus erlotinib showed response rates between 15% and 23% and PFS of about 4 months. However, the first study (64) was closed prematurely for two fatal gastrointestinal perforations and the second (65) concluded that the addition of erlotinib did not seem to contribute to efficacy.

A phase II study combined bevacizumab with temsirolimus in recurrent ovarian cancer reporting an objective response rate of 12% (66), whereas another trial, combining bevacizumab with sorafenib in bevacizumab naïve epithelial EOC patients, showed a response rate of 24% (all partial responses) (67).

Novel drugs targeting angiogenesis through alternative pathways

Blocking angiogenesis represents an effective therapeutic strategy leading to control EOC tumor growth. There are two primary strategies to inhibit the VEGF pathway: inhibition of the VEGF ligand with antibodies or soluble receptors and inhibition of the VEGFR with tyrosine kinase inhibitors (TKI) or receptor antibodies. Moreover, some studies are evaluating new drugs targeting multiple angiogenic pathways, including the PDGF and FGF pathways that could counteract resistance mechanisms and so enhance anti-angiogenic and antiproliferative effects (Fig. 1). Among drugs targeting VEGF pathway, there is VEGF Trap (aflibercept), a fusion protein consisting of the extracellular binding domains of human VEGF-1 and -2 linked through the Fc region of human IgG1. Aflibercept acts through VEGFA binding and neutralizing all VEGFA isoforms. A phase II study evaluating 162 patients with recurrent, platinum-resistant EOC showed similar response rates compared with bevacizumab administration (11% partial response), with acceptable toxicity profile and low incidence of bowel perforation (1%) (68,69).

Figure 1. Main mechanisms of angiogenesis in ovarian cancer and agents targeting angiogenesis through VEGF pathway and alternative pathways under evaluation in phase II–III trials.

There are now several small molecule inhibitors of VEGFR TKI inhibiting the VEGFR family and others, such as PDGFR, c-kit, which could be active in ovarian cancer. Pazopanib is a TKI that targets VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-α, PDGFR-β, and c-Kit was used in asymptomatic relapse with increasing Ca125, following complete response after first-line chemotherapy. The primary end-point was Ca125 response that was reported in 31% of cases (70). Subsequently, some studies have evaluated efficacy and safety of pazopanib in combination with cytotoxic drugs, as paclitaxel, carboplatin, cyclophosphamide, leading to controversial results.

Cediranib (AZD2171), an oral VEGFR-1, -2 and -3, PDGFRB and c-kit inhibitor, showed 17% objective response rates as monotherapy (71). Most patients (65%) had platinum-resistant disease. Currently, the ICON 6 trial is studying cediranib in platinum-sensitive patients with first relapse.

Sunitinib, an oral multi-target VEGF and PDGF receptor tyrosine kinase inhibitor with anti-angiogenic and antitumor activity, has been used in a phase II study of 30 recurrent ovarian cancer patients with a partial response and Ca125 response less than 10%. These results were observed only in platinum sensitive patients that represented 72% of all patients (72).

Sorafenib is a small molecule which inhibits cell proliferation by targeting the MEK/ERK signaling pathway through the inhibition of Raf-1 kinase and by inhibiting VEGF receptors. Several studies using sorafenib have been reported, but as monotherapy (73) or in combination with other cytotoxic agents (74–76), including gemcitabine, carboplatin, paclitaxel, topotecan, have shown limited efficacy in recurrent disease with often severe toxicities. Probably the most promising results with sorafenib have been reported in a study of sorafenib/bevacizumab combination (67).

Nintedanib (BIBF1120) is a triple TKI against VEGFR, PDGFR and FGFR. In a randomised maintenance trial nintedanib (BIBF1120)/placebo was given to patients who had responded and completed treatment for relapsed disease, with evidence of response (16% in patients receiving nintedanib and 5% on placebo), but at high risk of further early recurrence (77).

Cabozantinib, a highly potent TKI directed against VEGFR2 and the hepatocyte growth factor (HGF) receptor c-Met, has promising single-agent activity in recurrent ovarian cancer with a 24% objective response rate (78).

Imatinib mesylate inhibits abl, c-kit and PDGFR tyrosine kinases, but different phase II trials of imatinib mesylate in recurrent ovarian cancer showed no complete or partial responders (79).

Several EGFR and HER-2 inhibitors are also being tested in patients with ovarian cancer (erlotinib, gefitinib, trastuzumab, pertuzumab, cetuximab), but have shown only modest efficacy both in monotherapy and in association with other cytotoxic agents and bevacizumab.

Angiopoietins are circulating protein growth factors (Ang-1/Ang-2) that promote angiogenesis by binding Tie2 receptors. A recent phase II randomized trial demonstrated activity for the selective angiopoietin 1/2-neutralizing pepti-body, AMG 386, a peptide-Fc fusion protein that blocks the interaction between the Tie2 receptor and angiopoietin-1/2. A study evaluating AMG386 in combination with weekly paclitaxel showed prolongation of PFS (from 4.6 to 7.2 months, HR 0.76) (80). Currently, AMG386 is being tested in phase III trials both in first line (TRINOVA-3; NCT01493505) with carboplatin and paclitaxel and in the recurrent disease in combination with weekly paclitaxel (TRINOVA-1; NCT01204749).

Thalidomide has been demonstrated to have anti-angiogenic properties by blocking fibroblast growth factor and VEGF-induced angiogenesis. It also modulates the immune system by inducing production of interferon-γ, interleukin-2, and interleukin-10. A phase II trial has evaluated the efficacy of thalidomide plus topotecan in 69 women with recurrent EOC. The response rate for the group with thalidomide was 47 vs. 21% in the control group and PFS was significantly higher of two months for the thalidomide group (6 vs. 4 months), with similar toxicities (81). However, a study on thalidomide compared to tamoxifen did not show any activity on disease progression for maintenance therapy after complete remission from initial surgery and chemotherapy (82).

Volociximab (M200) is a monoclonal antibody that specifically binds integrins, which are important transmembrane proteins for vasculogenesis. Pre-clinical testing showed inhibition of proliferating endothelial cells by volociximab. However, a phase II, single-arm study of volociximab as monotherapy in patients with platinum-resistant advanced epithelial ovarian has showed insufficient clinical activity of volociximab (83).

Current and future developments

The most experience of anti-angiogenic therapy for patients with EOC resulted from the use of bevacizumab, but yet several trials are ongoing for identifying novel anti-angiogenic agents for EOC treatment in different setting. A better knowledge of several pathways involved in angiogenesis can help to select patients who might benefit from anti-angiogenic therapy with the discovery of predictive biomarkers and the identification of likely mechanisms of resistance to chemotherapy or targeted therapy, thus making anti-angiogenic therapies acceptable in terms of cost-effectiveness. Finally, future studies will need to focus also on optimal timing of anti-angiogenic agents and on possible combination of multiple targeted agents and/or cytotoxic chemotherapies. Despite the many unresolved questions, there is a growing body of evidence that targeting angiogenesis will lead to improved outcomes for women with ovarian cancer.

Abbreviations:

References